People’s Republic of China’s first patent for a COVID-19 (Coronavirus) vaccine has been granted by the National Intellectual Property Administration.
The patent was simultaneously applied for a research team with the Academy of Military Sciences and CanSino Biologics Inc., a Chinese high-tech biopharmaceutical company, stated a report in People’s Daily.
The team headed by Chen Wei, a researcher at the Institute of Military Medicine under the academy, developed the recombinant COVID-19 vaccine, with the qualified defective adenovirus as the vector.
In March, the vaccine enhanced the first in China to be approved to enter clinical trials.
According to the patent abstract, the vaccine shows good immunogenicity in both mouse and guinea pig models and can induce strong cellular and humoral immune response in a short period of time. It can be delivered quickly on a large scale to cope with a Coronavirus Pandemic.
The vaccine has now finished phase-1 and phase-2 clinical trials, which have verified its safety and immunogenicity, said the report.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
